Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amarin Corp ADR
(NQ:
AMRN
)
0.8475
-0.0725 (-7.88%)
Streaming Delayed Price
Updated: 9:52 AM EDT, May 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amarin Corp ADR
< Previous
1
2
3
4
5
6
Next >
Sarissa Capital Warns of Amarin’s Expensive Attempts to Switch Votes by Inundating Shareholders With White Proxy Cards
February 13, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Shareholders Invited to Webcast with Board and Management Team
February 13, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Does Not Believe Amarin Cares About Shareholders
February 09, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Mails Letter Highlighting Why Shareholders Should Vote on the WHITE Proxy Card “AGAINST” Sarissa’s Harmful Proposals
February 09, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Highlights Amarin’s Inaccurate and Misleading Statements
February 07, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Mails Letter to Shareholders Highlighting Sarissa’s Myths vs. The Facts
February 06, 2023
Company Files Investor Presentation and Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Highlights Amarin’s Disregard for Shareholder Interests and Urges Shareholders to Vote the BLUE Proxy Card for Change at Amarin
February 03, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
February 02, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders
February 01, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders
January 31, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand
January 27, 2023
Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at SVB Securities Global Biopharma Conference
January 27, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Responds to Inaccurate and Misleading Statement by Sarissa
January 19, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Calls Out Amarin’s Sham Board Refreshment
January 18, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders
January 11, 2023
Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen
January 10, 2023
From
Sarissa Capital Management LP
Via
Business Wire
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
January 10, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP
January 10, 2023
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 14, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland
December 07, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia
November 15, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at Jefferies London Healthcare Conference
November 09, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care
November 07, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
October 27, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Appoints Adam Berger and Geraldine Murphy to Board of Directors
October 20, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
October 20, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Board of Directors Issues Statement in Response to Sarissa
October 11, 2022
From
Amarin Corporation plc
Via
GlobeNewswire
Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members
October 11, 2022
From
Sarissa Capital Management LP
Via
Business Wire
3 Biotech Stocks Gaining Momentum
September 12, 2022
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.
Via
MarketBeat
MarketBeat: Week in Review 8/22 - 8/26
August 27, 2022
The markets are selling on news that interest rate hikes will continue past September. But here are some of the other stories for investors to follow this week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.